Clinical Trial

Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD

Study acronym: RESOLVE-CKD
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The overall objective of this pilot randomized clinical trial is to determine whether low-dose Colchicine (LoDoCo) improves vascular disease including vascular calcification, peripheral arterial disease (PAD), and chronic kidney disease-mineral and bone disorder (CKD-MBD) biomarkers in patients with chronic kidney disease (CKD) stage 3 over a 12-month intervention period, compared with usual care. Successful completion of this study will generate critical preliminary data to support a larger clinical trial aimed at evaluating inflammation-targeted therapies to mitigate CKD-MBD, including vascular calcification and related PAD, as well as osteoporosis, ultimately reducing cardiovascular events and mortality in patients with CKD. Additionally, this work has the potential to redefine the diagnostic framework for CKD-MBD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-11.
Trial Details
NCT Number NCT07654231
Lead Sponsor University of Texas Southwestern Medical Center
Conditions Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
Enrollment 60 participants
Start Date 2026-07-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22